Maria Pihlgren

IGI Technologies (United States) — United States

Medicine · Health Sciences

26h-index3.1kcitations63works5.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(22), Monoclonal and Polyclonal Antibodies Research(18), Immunotherapy and Immune Responses(16), T-cell and B-cell Immunology(13), Immune Cell Function and Interaction(10)

Publications63 total

554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)
Regular and Young Investigator Award Abstracts·2025Open Access
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
Journal of Clinical Oncology·2025· 4 cited
Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome
PLoS ONE·2025Open Access
Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients
Cancer Research·2025
Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients
Cancer Research·2025· 1 cited
First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2024· 8 citedOpen Access
ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection
Blood·2024Open Access
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Nature Cancer·2024· 29 citedOpen Access
T cell independent antibody responses with class switch and memory using peptides anchored on liposomes
npj Vaccines·2024· 10 citedOpen Access
Abstract 1238: ISB 2001, a BCMA and CD38 dual targeting T cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patient relapsing from CD38 and BCMA targeted immunotherapies
Cancer Research·2024
A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Blood·2023· 4 cited
Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma
Blood·2023· 1 citedOpen Access
Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma
Blood·2023· 19 citedOpen Access
Abstract 2970: Overcoming mechanisms of escape from treatments for multiple myeloma with ISB 2001, a potential first-in-class trispecific BCMA and CD38 targeted T cell engager
Cancer Research·2023· 1 cited
ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens
Blood·2022· 14 cited
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease
Science Translational Medicine·2021· 106 citedOpen Access
Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression
Scientific Reports·2018· 51 citedOpen Access
[P3–067]: DEVELOPMENT OF HIGHLY SENSITIVE MSD ASSAYS FOR THE DETECTION OF ANTI‐AMYLOID β MONOMER‐ AND OLIGOMER‐SPECIFIC ANTIBODIES IN HUMAN SERUM
Alzheimer s & Dementia·2017Open Access
[P4–099]: CHANGES IN TAU PROTEIN LANDSCAPE DURING ALZHEIMER's DISEASE PROGRESSION
Alzheimer s & Dementia·2017· 2 cited
Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope
Journal of Alzheimer s Disease·2016· 11 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Andrea Pfeifer(20), Andreas Muhs(19), Oskar Adolfsson(11), Claire‐Anne Siegrist(11), David T. Hickman(10), Paul‐Henri Lambert(10), Cyril Konto(9), Chantal Tougne(8), Valérie Giriens(8), Vinu Menon(8), Valérie Gafner(7), María Pilar López-Deber(7), Jacqueline Marvel(7), Mario Perro(7), Nathalie Chuard(6), Paola Bozzotti(6), Rime Madani(6), Lida Pacaud(6), Jasvinder K. Atwal(5), Pedro Reis(5)